The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment

Despite major improvements in treatment outcome with novel targeted therapies, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, chronic lymphocytic leukemia (CLL) remains incurable in the majority of patients. Activation of PI3K, NF-κB, and/or MYC has been linked to residual disease and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Kim, Ekaterina, ten Hacken, Elisa, Sivina, Mariela, Clarke, Astrid, Thompson, Philip A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G., Bhalla, Kapil N., Burger, Jan A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7272263/
https://ncbi.nlm.nih.gov/pubmed/31862959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0682-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados